Obesity Products Information | Scientific Exchange

Home > Novo Nordisk Inc. (NNI) Products > Obesity Products

Novo Nordisk Inc. (NNI) Products

Novo Nordisk has multiple products on the market for the treatment of Diabetes, Obesity, Growth Hormone Disorders, Hemophilia and Rare Bleeding Disorders. Access information and resources on each of our products below.

Obesity

Wegovy™

(semaglutide) injection 2.4 mg

Wegovy^™ (semaglutide) injection is initiated at a dose of 0.25 mg once weekly for 4 weeks. The dose should be increased at 4-week intervals, following the dose escalation schedule, until a dose of 2.4 mg once weekly is reached. For more information about the dose escalation schedule for Wegovy^™, please see the Prescribing Information.

Wegovy^™ (semaglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Safety Data Sheet | Storage & Stability

Prescribing Information

Saxenda^®

(liraglutide) injection 3 mg

Saxenda^® (liraglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) and in pediatric patients aged 12 years and older with body weight above 60 kg and an initial BMI corresponding to 30 kg/m2 or greater for adults (obese) by international cut-offs.

Safety Data Sheet | Storage & Stability

Prescribing Information

obesity

Explore

Additional Information

Speak to a live medical representative.

If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit https://www.novonordisk-us.com/contact-us.html or call 1-800-727-6500

Start Conversation

Search the Medical Information Database

The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.

Begin Search

Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.